Survival After Neoadjuvant Therapy Compared with Surgery Alone for Resectable Esophageal Cancer in a Population‐based Study

Rouvelas, Ioannis; Zeng, Wei; Lindblad, Mats; Viklund, Pernilla; Ye, Weimin; Lagergren, Jesper

doi:10.1007/s00268-006-0016-6

Cited by 20 publications

(12 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…nCRT has been shown to give more tumour regression, increase R0 resection rates and reduce the risk of lymph node metastasis, but none of these trials showed any statistically significant benefit regarding survival. Patients who respond to treatment with complete histological response have increased survival compared with non‐responders.…”

Section: Introductionmentioning

confidence: 99%

Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry

Klevebro

Lindblad

Johansson

et al. 2016

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry

Klevebro

Lindblad

Johansson

et al. 2016

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…Furthermore, the implementation of preoperative CRT was extensive and fast, which could probably be explained by the usage of embedded logistics within the framework of the Dutch CROSS trial as radiotherapy institutes in the Netherlands are mostly independent from hospitals and patients need to be referred. Even though the implementation of preoperative CRT was early and possibly premature in the Netherlands, it seems that the extensive administration of preoperative CRT was even earlier in Sweden [17].…”

Section: Multimodality Treatment Trendsmentioning

confidence: 99%

Recent trends and predictors of multimodality treatment for oesophageal, oesophagogastric junction, and gastric cancer: A Dutch cohort-study

et al. 2015

View full text Add to dashboard Cite

background. In recent years, evidence supporting multimodality treatment for oesophageal, oesophagogastric junction (OGJ), and gastric cancer has accumulated. This population-based cohort-study investigates trends and predictors of utilisation of multimodality treatment for oesophagogastric cancer in the Netherlands. Patients and methods. Data were obtained from the Netherlands Cancer Registry regarding patients with oesophageal (n  5450), OGJ (n  2168) and gastric cancer (n  6683) without distant metastases who had undergone R0 or R1 surgery diagnosed between 2000 and 2012. Follow-up was completed until February 2014. Preoperative/postoperative chemotherapy and/or radiotherapy combined with surgery were considered multimodality treatment. Logistic regression analysis was performed to analyse the association of age, gender, socioeconomic status, clinical T and N classification, hospital type, comprehensive cancer centre network region, and year of diagnosis, with multimodality treatment receipt. Additional analyses were performed to explore differences in trends of utilisation of multimodality treatment between academic and non-academic hospitals. results. Multimodality treatment utilisation for oesophageal, OGJ and gastric cancer increased significantly to 90%, 85% and 56% in 2012, respectively. In oesophageal and OGJ cancer patients, preoperative chemoradiotherapy was most frequently administered (85% and 47% in 2012, respectively), and in gastric cancer patients preoperative chemotherapy (47% in 2012). Lower age, higher clinical T and N classification, and diagnosis in more recent years were significantly associated with more frequent multimodality treatment receipt. The adoption of most types of multimodality treatment in academic hospitals preceded non-academic hospitals by a year. conclusion. In the Netherlands, the utilisation of multimodality treatment for oesophagogastric cancer has significantly increased during the past decade, especially in oesophageal and OGJ cancer. Multimodality treatment utilisation was especially dependent on patient and tumour characteristics and year of diagnosis, but multimodality treatment trends seem to be related to the publication of landmark studies, participation in nationally running clinical trials, and hospital type, preceding national guidelines.

show abstract

“…Since the time of initiating the reorganisation of cancer services, survival of patients undergoing curative surgery has improved from 34% for oesophageal tumours and 40% for gastric tumours to 45% and 50%, respectively [16,17]. Whilst these improvements can not directly be related to the reorganization of services, it is plausible that the concentration of curative surgery brought about improvements in survival in this group of patients.…”

Section: Resultsmentioning

confidence: 99%

Re-organisation of oesophago-gastric cancer services in England and Wales: a follow-up assessment of progress and remaining challenges

et al. 2014

View full text Add to dashboard Cite

BackgroundThis study is an update on an earlier article in 2007 to assess the implementation of the Cancer Plan reform strategy in England and Wales.FindingsA national online survey to upper gastro-intestinal leads at network and trust level. The questionnaire was designed based on existing clinical practice guidelines and addressed governing principles and operational procedures related to the delivery of cancer care. It was sent in January 2012 to upper gastro-intestinal network and trusts leads at all cancer networks and acute NHS organisations in England and Wales. Responses were received from 100% of Cancer Networks and 91% of NHS organisations. Centralisation of surgery has improved with all but two trusts (5.4%) now meeting the minimum staffing level for oesophago-gastric cancer surgery. This is a substantial improvement since the 2007 survey when 21 trusts (46.7%) did not meet this requirement. The use of formal assessment for nutritional needs has improved, too. In 2007, the involvement of the palliative care team in multi-disciplinary teams was poor. While this has improved, 27 trusts (19.7%) still report that none of the palliative care team members routinely attend the multi-disciplinary team discussion.ConclusionsThe survey demonstrates improved compliance with organisational recommendations since the last assessment in 2007. Centralisation of surgery has improved and is nearly fully compliant with the reform strategy. Areas that require further improvement are nutritional support and inclusion of palliative care in multi-disciplinary team meetings.

show abstract

Survival After Neoadjuvant Therapy Compared with Surgery Alone for Resectable Esophageal Cancer in a Population‐based Study

Abstract: Surgical outcomes with and without neoadjuvant therapy were equivalent. Only patients with a complete histopathological response after neoadjuvant treatment had better survival.

Cited by 20 publications

References 49 publications

Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry

Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry

Recent trends and predictors of multimodality treatment for oesophageal, oesophagogastric junction, and gastric cancer: A Dutch cohort-study

Re-organisation of oesophago-gastric cancer services in England and Wales: a follow-up assessment of progress and remaining challenges

Contact Info

Product

Resources

About